Key Takeaways
- • GlaxoSmithKline launches Action Potential Venture Capital Limited, a $50 million strategic venture capital fund focused exclusively on bioelectronic medicines and technologies, with plans to build a portfolio of five to seven companies by 2018.
- • SetPoint Medical, a California-based developer of implantable devices for treating inflammatory diseases, receives the fund's first investment, positioning GSK at the forefront of an emerging therapeutic category.
- • The venture fund complements GSK's Bioelectronics R&D unit (established in 2012) and reflects the pharmaceutical giant's systematic effort to integrate emerging science in neuromodulation across a broad therapeutic spectrum.
- • Target indications span inflammatory bowel disease, rheumatoid arthritis, asthma, COPD, and Type 2 diabetes—disorders where miniaturized bioelectronic devices could modulate peripheral nervous system signals to therapeutic effect.
- • The fund's nomenclature derives from "action potentials," the electrical impulses traversing nerves; GSK's thesis positions bioelectronic medicines as capable of reading, modifying, or generating these impulses to treat disease.
Summary
GlaxoSmithKline announced on August 8, 2013, the establishment of Action Potential Venture Capital Limited, a $50 million strategic venture capital fund dedicated to identifying and financing pioneering companies in bioelectronic medicines and associated technologies. This capital deployment represents GSK's systematic commitment to a nascent therapeutic domain characterized by miniaturized implantable devices designed to interface with the peripheral nervous system.
The fund's inaugural investment targets SetPoint Medical, a California-based company specializing in implantable devices for inflammatory disease treatment. This selection reflects GSK's identification of SetPoint as a category leader in translating bioelectronics from laboratory science into clinical application. The venture capital vehicle operates in tandem with GSK's dedicated Bioelectronics R&D unit, which the company established in 2012 following a two-year period of investigative work to identify and engage leading researchers in the field.
GSK's investment thesis centers on the therapeutic manipulation of action potentials—electrical signals propagating along peripheral nerves. The company posits that irregular or altered patterns of these impulses correlate with a diverse array of pathologies. Through engineered bioelectronic devices, GSK envisions the capacity to read, modify, or generate electronic impulses capable of treating conditions spanning inflammatory bowel disease, rheumatoid arthritis, respiratory diseases such as asthma and COPD, and metabolic disorders including Type 2 diabetes.
The venture capital structure targets portfolio construction of five to seven companies through 2018, positioning GSK for strategic exposure to technological advancement in an embryonic field. By funding external innovators while maintaining internal R&D capabilities, GSK creates a dual-track strategy to accelerate scientific integration and potential clinical translation in bioelectronic therapeutics.
The fund's inaugural investment targets SetPoint Medical, a California-based company specializing in implantable devices for inflammatory disease treatment. This selection reflects GSK's identification of SetPoint as a category leader in translating bioelectronics from laboratory science into clinical application. The venture capital vehicle operates in tandem with GSK's dedicated Bioelectronics R&D unit, which the company established in 2012 following a two-year period of investigative work to identify and engage leading researchers in the field.
GSK's investment thesis centers on the therapeutic manipulation of action potentials—electrical signals propagating along peripheral nerves. The company posits that irregular or altered patterns of these impulses correlate with a diverse array of pathologies. Through engineered bioelectronic devices, GSK envisions the capacity to read, modify, or generate electronic impulses capable of treating conditions spanning inflammatory bowel disease, rheumatoid arthritis, respiratory diseases such as asthma and COPD, and metabolic disorders including Type 2 diabetes.
The venture capital structure targets portfolio construction of five to seven companies through 2018, positioning GSK for strategic exposure to technological advancement in an embryonic field. By funding external innovators while maintaining internal R&D capabilities, GSK creates a dual-track strategy to accelerate scientific integration and potential clinical translation in bioelectronic therapeutics.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.